Stock Traders Buy Large Volume of Alnylam Pharmaceuticals Call Options (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) saw some unusual options trading activity on Monday. Investors purchased 12,128 call options on the stock. This is an increase of approximately 710% compared to the average volume of 1,497 call options.

ALNY opened at $187.97 on Wednesday. The company has a fifty day simple moving average of $189.16 and a 200 day simple moving average of $161.23. The firm has a market cap of $22.34 billion, a price-to-earnings ratio of -24.77 and a beta of 1.22. Alnylam Pharmaceuticals has a twelve month low of $119.29 and a twelve month high of $209.73. The company has a current ratio of 4.91, a quick ratio of 4.76 and a debt-to-equity ratio of 0.51.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Monday, August 2nd. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($1.61). Alnylam Pharmaceuticals had a negative net margin of 128.96% and a negative return on equity of 88.43%. The business had revenue of $220.55 million during the quarter, compared to analyst estimates of $193.66 million. During the same period last year, the business earned ($1.67) EPS. The business’s revenue was up 112.1% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals will post -6.15 earnings per share for the current fiscal year.

ALNY has been the topic of a number of recent analyst reports. Morgan Stanley increased their price target on shares of Alnylam Pharmaceuticals from $224.00 to $234.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 4th. Piper Sandler lowered shares of Alnylam Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $45.00 to $47.00 in a research report on Wednesday, August 4th. Chardan Capital reissued a “buy” rating and issued a $190.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 4th. BMO Capital Markets increased their price objective on shares of Alnylam Pharmaceuticals from $174.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, August 27th. They noted that the move was a valuation call. Finally, Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $196.00 to $216.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 4th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $169.33.

In related news, insider Akshay Vaishnaw sold 14,708 shares of the company’s stock in a transaction that occurred on Friday, June 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,573,900.00. Following the transaction, the insider now owns 24,953 shares of the company’s stock, valued at $4,366,775. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO John Maraganore sold 33,979 shares of the company’s stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $199.78, for a total transaction of $6,788,324.62. Following the transaction, the chief executive officer now directly owns 248,744 shares in the company, valued at approximately $49,694,076.32. The disclosure for this sale can be found here. Insiders sold 118,563 shares of company stock worth $23,030,536 in the last ninety days. Insiders own 2.30% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sowell Financial Services LLC boosted its stake in Alnylam Pharmaceuticals by 54.9% during the 1st quarter. Sowell Financial Services LLC now owns 333 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 118 shares during the last quarter. Wolverine Asset Management LLC boosted its stake in Alnylam Pharmaceuticals by 3,023.1% during the 1st quarter. Wolverine Asset Management LLC now owns 406 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 393 shares during the last quarter. IFP Advisors Inc boosted its stake in Alnylam Pharmaceuticals by 914.3% during the 2nd quarter. IFP Advisors Inc now owns 355 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 320 shares during the last quarter. HM Payson & Co. boosted its stake in Alnylam Pharmaceuticals by 121.4% during the 1st quarter. HM Payson & Co. now owns 465 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 255 shares during the last quarter. Finally, Capital Analysts LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $68,000. Hedge funds and other institutional investors own 93.34% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm’s products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.

Further Reading: Institutional Investors

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.